Journal of Clinical Oncology, Vol 18, Issue 2
(January), 2000: 284
© 2000 American Society for Clinical Oncology
Tamoxifen Should be Cost-Effective in Reducing Breast Cancer Risk in High-Risk Women
By Thomas J. Smith,
Bruce E. Hillner
From the Department of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.
Address reprint requests to Thomas J. Smith, MD, Division of Hematology/Oncology, 1101 East Marshall St, PO Box 980230, Richmond, VA 23298-0230; email tsmith{at}mcc1.mcc.vcu.edu
PURPOSE: To estimate the cost-effectiveness of tamoxifen in the prevention of breast cancer.
PATIENTS AND METHODS: Clinical trial results of National Surgical Adjuvant Breast Program P-1 compared tamoxifen versus placebo in the prevention of breast cancer, and direct medical care costs were estimated from the Agency for Health Care Policy and Research and local sources. The base estimate of effectiveness included all women on the trial.
RESULTS: For every 100 women treated for 5 years, 1.665 expected cancers would not be detected. If breast cancer death is fully prevented by this strategy, then the cost-effectiveness of tamoxifen compared with no intervention is $8,479 per additional year of life gained. If lifetime prevention of the risk of death from breast cancer exceeded 17%, then the cost-effectiveness ratio would be less than $50,000 per year of life gained (a common benchmark).
CONCLUSIONS: Tamoxifen for breast cancer prevention should be cost-effective under nearly all circumstances. Its use will require additional resources because it is not cost saving, but it fits within accepted guidelines.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. R. Cummings, J. S. Lee, L.-Y. Lui, K. Stone, B. M. Ljung, J. A. Cauleys, and for the Study of Osteoporotic Fractures Research G
Sex Hormones, Risk Factors, and Risk of Estrogen Receptor-Positive Breast Cancer in Older Women: A Long-term Prospective Study
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2005;
14(5):
1047 - 1051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mandelblatt, C. Armetta, K. R. Yabroff, W. Liang, and W. Lawrence
Descriptive Review of the Literature on Breast Cancer Outcomes: 1990 Through 2000
J Natl Cancer Inst Monographs,
October 1, 2004;
2004(33):
8 - 44.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. F. Col, R. J. Goldberg, R. K. Orr, J. K. Erban, J. M. Fortin, and R. T. Chlebowski
Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model
Med Decis Making,
October 1, 2002;
22(5):
386 - 393.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. T. Chlebowski, N. Col, E. P. Winer, D. E. Collyar, S. R. Cummings, V. G. Vogel III, H. J. Burstein, A. Eisen, I. Lipkus, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition
J. Clin. Oncol.,
August 1, 2002;
20(15):
3328 - 3343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hershman, V. Sundararajan, J. S. Jacobson, D. F. Heitjan, A. I. Neugut, and V. R. Grann
Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis
J. Clin. Oncol.,
January 1, 2002;
20(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Warren, M. L. Brown, M. P. Fay, N. Schussler, A. L. Potosky, and G. F. Riley
Costs of Treatment for Elderly Women With Early-Stage Breast Cancer in Fee-for-Service Settings
J. Clin. Oncol.,
January 1, 2002;
20(1):
307 - 316.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
